Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Global X Robo Global Robotics & Automation ETF (ROBO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Global X Robo Global Robotics & Automation ETF — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.88 (market cap $4.49B), while Global X Robo Global Robotics & Automation ETF trades at $80.8. Which is the better fit depends on your goals.
| ACAD | ROBO | |
|---|---|---|
Market Cap | $4.49B | — |
Sector | Health | Sector/Thematic |
52-Week High | $28.06 | $90.34 |
52-Week Low | $20.06 | $60.15 |
Enterprise Value | $3.69B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
ROBO trades at $86.19, up 3.36% today, with a bullish technical signal from moving averages and neutral oscillators. Recent news highlights the ETF's rebalancing toward AI infrastructure and physical automation themes, positioning it to benefit from the expanding robotics and AI ecosystem. Key support lies at $85, with resistance at $87.
The outlook is positive, driven by thematic tailwinds in robotics and AI infrastructure, though valuation metrics are unavailable. Risks include cyclical exposure and reliance on AI adoption. Analyst sentiment is cautiously optimistic, with institutional interest growing in physical AI themes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Global X Robo Global Robotics & Automation ETF
ROBO is a thematic ETF that tracks the global robotics and automation industry. It provides diversified exposure to companies leading in industrial robotics, 3D printing, and surgical systems, with holdings like Intuitive Surgical and Zebra Technologies.
Read more on ROBO →
